Suchen
NewAmsterdam Pharma Company NV
NAMSZur Watchlist hinzufügen
33.890USD
+0.020+0.06%
Handelsschluss 06/30, 16:00（ET）Kurse um 15 Minuten verzögert
3.96BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über NewAmsterdam Pharma Company NV Unternehmen
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
NewAmsterdam Pharma Company NV Informationen
BörsenkürzelNAMS
Name des UnternehmensNewAmsterdam Pharma Company NV
IPO-datumNov 23, 2022
CEODavidson (Michael Harvey)
Anzahl der mitarbeiter68
WertpapierartOrdinary Share
GeschäftsjahresendeNov 23
AddresseGooimeer 2-35
StadtNAARDEN
BörseNASDAQ OMX - NASDAQ BASIC
LandNetherlands
Postleitzahl1411 DC
Telefon31352062971
Websitehttps://ir.newamsterdampharma.com/
BörsenkürzelNAMS
IPO-datumNov 23, 2022
CEODavidson (Michael Harvey)
Führungskräfte von NewAmsterdam Pharma Company NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Nicholas Downing, M.D.
Dr. Nicholas Downing, M.D.
Director
Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von NewAmsterdam Pharma Company NV?
Die fünf größten Anteilseigner von NewAmsterdam Pharma Company NV sind: Mr. John W. Smither
Wie viele Institutionen halten Anteile an NewAmsterdam Pharma Company NV (NAMS)?
Mit Stand vom 2026Q1 halten 366 Institutionen Anteile an NewAmsterdam Pharma Company NV, mit einem Gesamtmarktwert von etwa 128.70M, was 110.09% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 2432976.00 gestiegen.